KRAS and non-small cell lung carcinoma: A clinically approved treatment targeting this mutation in non-small cell lung cancer (NSCLC) [36] is available but unfortunately, the respective publication in our analysis did not indicate the specific KRAS mutation linked to the reported worse LRC.